Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-R117C in HLA-A*02:01-positive PIWIL1-positive advanced cancers
NCT06840119Phase 2Recruiting
- Sponsor
- Immunocore
- Start
- Jan 2024
- Primary completion
- Nov 2026
- Modality
- Antibody Conjugates, Small Molecules, Bispecific Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of IMC-R117C in colorectal cancer (CRC), esophageal cancer, gastric cancer (GC) and 1 more (4 arms), sponsored by Immunocore. Primary endpoints: Dose-Limiting Toxicity at 24 months, Adverse Events at 24 months and 6 more. Started Jan 2024; status: recruiting.
02
Drugs
IMC-R117C
03
Conditions
colorectal cancer (CRC)esophageal cancergastric cancer (GC)ovarian cancer
Beyond the preview
Go deeper on NCT06840119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06840119.